Infectious disease Archives

Atriva Therapeutics seed funding Influenza

News and Trends 8 Feb 2017

German Biotech gets Seed Funding to Repurpose Cancer Drugs for the Flu

Atriva Therapeutics has received seed funding to advance the development of a better therapy for influenza in patients at high risk. Atriva Therapeutics was founded in Tübingen, Germany in 2015 with a quite particular aim: repurposing cancer drugs to treat influenza. Two private investors, the Dutch Stichting Participatie Atriva and the German High-Tech Gründerfonds (HTGF) have contributed with […]

February 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 6 Feb 2017

“We want to be the Worldwide Leader in Microbiota”

Biotech entrepreneur Hervé Affagard, CEO of MaaT Pharma, tells the story behind the success of his young microbiome company. Hervé Affagard is the CEO and co-founder of a company with an ambitious goal: become the global leader in treating the gut microbiota. Founded in 2014 and based in Lyon, MaaT pharma wants to employ fecal transplants to treat […]

February 6, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Feb 2017

Stem Cell Therapy for Sepsis in Pneumonia advances to Phase II

TiGenix has treated the first patient in a new early-stage clinical trial to test its candidate Cx611 as a treatment for sepsis in patients with pneumonia. TiGenix, based in Belgium, develops stem cell therapies derived from donors. This morning, the first patient was treated in a Phase Ib/IIa clinical trial for its candidate therapy Cx611 in […]

February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Jan 2017

‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier

Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired antibody fragments, VNARs, with outstanding properties thanks to their small size and high solubility. The company has now received a milestone payment from Danish pharma Lundbeck for the development of the technology as a delivery […]

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 25 Jan 2017

Genetically Engineered Mosquitoes will arrive in India to fight Dengue

Oxitec is preparing to start trials testing its solution to reduce the population of disease-transmitting insects in India with its own genetically modified mosquitoes. Oxitec, a spin-out from Oxford University, engineers mosquitoes to reduce their populations in areas where they spread infectious diseases. After success in Brazil and the Cayman Islands, the company is now heading […]

January 25, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Screenshot 2017 01 23 at 3.58.16 PM 1 e1485183691824

News and Trends 23 Jan 2017

New Fundraising Boosts Ultra-Rapid STD Detection

Atlas Genetics has raised €32.6M in Series D. The funds will help the company bring ultra-rapid diagnostic tests for STDs to the market. Atlas Genetics, a spin-off from the University of Bath, has closed an impressive €32.6M ($35M) Series D round of fundraising. The funds will support clinical trials, manufacturing and the commercial launch of the company’s second ultra-rapid […]

January 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 17 Jan 2017

Nanoparticles from Car Tailpipes could Activate Viruses in the Lungs

Nanoparticles produced by burning fossil fuels could promote viral infections by activating latent viruses in our lungs; what are the consequences? We all know that breathing the traffic smoke is not good for our health. Now, researchers from the Helmholtz Zentrum in Munich have discovered a process that makes it even more dangerous than initially […]

January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Jan 2017

This Herpes Cure is Proving to Work Better than its Predecessors

AiCuris’ candidate pritelivir has shown to perform better than current standard antiviral treatments against genital herpes in Phase II trials. AiCuris, leading the development of treatments for infectious disease, has completed a Phase II trial in which its candidate pritelivir outperformed the current standard care for genital herpes. When compared to the antiviral drug valacyclovir, […]

January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Jan 2017

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

Ablynx has treated its first patient in a new trial targeting RSV infections, the main cause of children hospitalizations. Ablynx, one of the few European biotechs that made it into JP Morgan this year, develops nanobodies derived from llamas. The Belgian company announced yesterday that its candidate ALX-0171 has entered testing in Phase IIb as a treatment […]

January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Jan 2017

Phase II Failure: CureVac’s CEO explains Missed Efficacy Endpoint

Money doesn’t guarantee success, even if it’s heavy investment from the likes of the Bill & Melinda Gates Foundation. Ingmar Hoerr explains what it means for mRNA therapeutics. In a blow to the field of mRNA, the German billion-euro biotech CureVac has reported the Phase II failure of its lead candidate at JP Morgan. Aimed at prostate cancer, CV9104 did not […]

January 11, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 4 Jan 2017

Cold Sore Cure Company enters the Antibiotic Resistance fight

AiCuris is developing a new antibiotic that might bring hope for patients in which all options to fight infections have been exhausted. AiCuris, a German company leading the fight against infectious diseases, is now entering clinical trials with a new antibiotic. The candidate, AIC499, is a β-lactam effective against a broad range of Gram-negative multi-drug resistant […]

January 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Jan 2017

Bacteria can Protect each other: a New Challenge in Antibiotic Resistance

Researchers have discovered a new mechanism by which antibiotic-resistant bacteria can protect non-resistant pathogens. What are the implications? Scientists have described a new strategy that pathogens use to survive our efforts to eliminate them: resistant bacteria can inactivate antibiotics and allow their neighbor pathogens to grow once the active compound has reached low enough levels. The […]

January 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Infectious disease

German Biotech gets Seed Funding to Repurpose Cancer Drugs for the Flu

“We want to be the Worldwide Leader in Microbiota”

Stem Cell Therapy for Sepsis in Pneumonia advances to Phase II

‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier

Genetically Engineered Mosquitoes will arrive in India to fight Dengue

New Fundraising Boosts Ultra-Rapid STD Detection

Nanoparticles from Car Tailpipes could Activate Viruses in the Lungs

This Herpes Cure is Proving to Work Better than its Predecessors

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

Phase II Failure: CureVac’s CEO explains Missed Efficacy Endpoint

Cold Sore Cure Company enters the Antibiotic Resistance fight

Bacteria can Protect each other: a New Challenge in Antibiotic Resistance

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!